Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Palliate care is concerned with oncologic patients and its aim is to reduce their suffering, i.e. in the first place to eliminate or reduce pain. As a rule, the WHO prescriptions are followed, administering progressively nonsteroid analgesic agents (NSAIDs), weak opioids, strong opioids. The most convenient channels of administration are oral and subcutaneous. So far, NSAIDs could not be given subcutaneously due to the local side effects (pain and irritation at the point of injection) they cause. On the basis of experience with tenoxicam in our Department, subcutaneous administration is suggested. Our study involved 27 subjects with treatment-refractory tumors, in order to assess topical tolerability. In all cases, the drug was administered via a subcutaneous permanent teflon needle-catheter. Tenoxicam was found to have better gastric tolerability compared to other NSAIDs. It can be concluded that for the palliative treatment of cancer patients tenoxicam ampoules are an additional drug that can be administered subcutaneously.
 ...
PMID:[The subcutaneous administration of a NSAID in palliative care]. 128 64

Tenoxicam is a long-acting nonsteroidal anti-inflammatory agent that appears to have the ability to control pain of musculoskeletal origin. A double-blind randomized crossover study was designed to determine the efficacy of tenoxicam for pain relief following third molar surgery by comparing it with paracetamol. Immediately before surgery, 30 Chinese patients with bilateral symmetrically impacted mandibular third molars were given 40 mg of tenoxicam for surgery on one side and 1,000 mg of paracetamol for surgery on the other. Both paracetamol and tenoxicam were efficient as pain relievers after third molar surgery. Tenoxicam had comparable efficacy to paracetamol, but did not provide any advantage in terms of duration of action. The discrepancy between the clinical observation and pharmacokinetic prediction may be related to the strong serum binding property of tenoxicam.
Anesth Pain Control Dent 1992
PMID:Tenoxicam for pain relief following third molar surgery. 129 91

This study reports on the efficacy of a single preoperative administration of Tenoxicam (20 mg intramuscular) after removal of two or more impacted molars. The recording of postoperative pain and swelling on a categorical and linear scale showed that there were no significant differences between the experimental and control groups. However, a significant reduction in pain was noted on the first postoperative day. We concluded that a single dose of Tenoxicam administered one hour preoperatively did have a significant analgesic effect, even though there was no significant reduction in postoperative swelling. Patients who did not have the injection had a 5.37 greater change of having more postoperative pain than those who were injected with Tenoxicam.
 ...
PMID:[Evaluation of Tenoxicam for control of postoperative pain and swelling following surgical removal of impacted molars]. 182 Jun 75

A randomized study was performed on 24 patients with ankylosing spondylitis to compare the efficacy and tolerability of 20 mg tenoxicam daily with 50 mg diclofenac twice daily. There were 6 withdrawals from the group taking tenoxicam and 4 from the diclofenac group. Depression in 1 patient taking tenoxicam was the only significant adverse event. Both drugs were otherwise well tolerated. Tenoxicam and diclofenac were rated as good or excellent by 27% and 55% of patients, respectively. Global assessment, pain and duration of morning stiffness were improved with both drugs but this improvement was not statistically significant and there was no statistically significant difference between the two groups. This study confirms that tenoxicam is effective and well tolerated but larger numbers would be required to detect a small difference between groups.
 ...
PMID:Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. 217 70

The efficacy of a new nonsteroidal anti-inflammatory agent, Tenoxicam, was valued in a study of 58 patients distinguished into 3 groups, group A consist of 29 patients with inflammatory diseases of the mouth, group 1B and 2B (29 patients) with acute postoperative pain. Drug was given at doses of: 1) 20 mg/die in group A; 2) 40 mg/die for the first two days and 20 mg/die for successive days in group 1B; 3) 20 mg/die in group 2B, for a period variable from 5 to 7 days. The outcomes showed that the administration of Tenoxicam resulted in a effective reduction of all inflammatory valued parameters (fever in 100%, inflammatory pain in 94% and edema in 90% of all cases) for the group A: acute postoperative pain was significantly reduced in group 1B where the patients have assumed drug at dose of 40 mg/die for the first two days and 20 mg/die for successive days. In group 2B (20 mg/die) drug's smaller dose showed reduced efficacy for control of postoperative pain. Although Tenoxicam was well tolerated and mild side effects were recorded only in 5% of cases.
 ...
PMID:[Tenoxicam in treatment of oral inflammation and pain]. 221 43

Tenoxicam is a thienothiazine derivative with marked analgesic and anti-inflammatory activities. The parenteral application of tenoxicam is especially suitable for initial therapy in acute and painful rheumatic conditions. The pharmacokinetic behaviour of tenoxicam after i.m., i.v. and p.o. administration did not differ, with the exception that higher plasma concentrations were reached during the first two hours after the parenteral dose. After both i.m. and i.v. application, tenoxicam showed a rapid onset of action, and reliable improvement of pain status. Tenoxicam was well tolerated both systemically and locally. About 10% of all patients experienced adverse events characteristic of non-steroidal anti-inflammatory drugs (NSAIDs).
 ...
PMID:Tenoxicam used as a parenteral formulation for acute pain in rheumatic conditions. 259 44

The effects of a nocturnal nonsteroidal anti-inflammatory drug (tenoxicam) on twelve male osteoarthritic patients were investigated in a randomised, double-blind, placebo-controlled, cross-over study. Tenoxicam produced no significant changes in any of the areas evaluated which included electroencephalographic (EEG) sleep, subjective sleep, pain and early morning stiffness. The selection of patients may have contributed to this unexpected result. There was no evidence to suggest that tenoxicam caused any unwanted side-effects or affected early morning psychomotor performance. The use of the sleep EEG as an objective pain measure is discussed.
 ...
PMID:The evaluation of a nonsteroidal anti-inflammatory drug (tenoxicam) in the treatment of sleep disturbance in osteoarthritic patients. 269 48

The therapeutic activity of tenoxicam, a thienothiazine derivative with analgesic and anti-inflammatory properties, has been studied by 15 investigators in Argentina and Brazil. Twenty-nine clinical trials were performed in a total of 747 patients suffering from rheumatoid arthritis (270), cox- and gonarthrosis (190), extra-articular inflammation (250) and acute gout (37). Out of the patients studied, 507 received tenoxicam and 240 were given comparative preparations. In 76% of the patients 20 mg tenoxicam was given as a single daily dose. In most patients duration of treatment was either six weeks or six months. Therapeutic results were evaluated according to the evolution of pain in various conditions as well as that of the articular, clinical and functional status. Once treatment was concluded a global evaluation of efficacy and tolerance was performed. The statistical analysis showed a significant improvement, in comparison to baseline, in all parameters considered under the different conditions. Double-blind studies showed no significant statistical differences between tenoxicam and the comparative preparations. Tolerance to tenoxicam was considered excellent, granting that some patients referred to adverse effects of the gastrointestinal type, such as epigastric discomfort, pyrosis and flatulence of moderate intensity. Tenoxicam is a new non-steroidal anti-inflammatory compound which is well tolerated and has excellent activity in the treatment of diverse rheumatoid conditions.
 ...
PMID:Evaluation of tenoxicam in rheumatology--clinical trial results in Argentina and Brazil. 332 8

Tenoxicam (20 mg/day) and piroxicam (20 mg/day) were compared in a double-blind, parallel group study over 4 weeks in 30 patients with ankylosing spondylitis. Both tenoxicam and piroxicam reduced spinal pain, but the improvement was greater with piroxicam. Tenoxicam and piroxicam were equally effective at improving duration of morning stiffness. Slight improvement was seen with other symptoms with both treatments. Patients were slightly more tolerant of piroxicam than tenoxicam and most patients elected to continue on their particular therapy at the end of the study.
 ...
PMID:A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. 351 71

A randomized double-blind trial with tenoxicam 10 mg/d and 20 mg/d and placebo was carried out for 2 weeks in 90 patients suffering from various extra-articular inflammatory conditions. Statistical analysis revealed significant differences in favour of tenoxicam as regards improvement of all parameters with an intensity which was moderate or severe at baseline, e.g. tenderness, mobility pain, functional limitation. The efficacy of tenoxicam at both dosages was similar (no statistically significant difference). Tenoxicam was well tolerated but some mild adverse reactions were observed in all three treatment groups.
 ...
PMID:Tenoxicam in soft-tissue rheumatism. 351 89


1 2 3 Next >>